These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6726624)

  • 1. Comparative bioavailability of two furosemide formulations in humans.
    Martin BK; Uihlein M; Ings RM; Stevens LA; McEwen J
    J Pharm Sci; 1984 Apr; 73(4):437-41. PubMed ID: 6726624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bioequivalence study of two products of furosemide tablets.
    Awad R; Arafat T; Saket M; Saleh M; Gharaibeh M; Zmeili S; Sallam E; Shubair M; Qobrosi S
    Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):18-23. PubMed ID: 1551740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers.
    Ogata H; Zugarni S; Ejima A; Kawatsu Y
    Eur J Clin Pharmacol; 1983; 24(6):791-6. PubMed ID: 6688397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations.
    Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; Yánez C; López de Ocáriz A; Solinís MA; Pedraz JL
    Arzneimittelforschung; 2003; 53(5):321-9. PubMed ID: 12854359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penbutolol and furosemide in a fixed-dose combination-bio-equivalence of two formulations.
    Meyer BH; Müller FO; Hundt HK; Grigoleit HG; Hajdu P; Heptner W
    S Afr Med J; 1981 Jun; 59(25):891-3. PubMed ID: 7015536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence between two furosemide-spironolactone formulations: a pharmacokinetic and pharmacodynamic approach.
    Schütz W; Freissmuth M; Tuisl E; Blöchl-Daum B; Eichler HG; Loew D
    Curr Med Res Opin; 1991; 12(7):450-8. PubMed ID: 1778087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.
    Alván G; Paintaud G; Eckernäs SA; Grahnén A
    Br J Clin Pharmacol; 1992 Jul; 34(1):47-52. PubMed ID: 1633067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of two preparations of frusemide.
    Paton DM
    N Z Med J; 1980 Mar; 91(656):208-10. PubMed ID: 6929997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and pharmacokinetics of furosemide marketed in Thailand.
    Kaojarern S; Poobrasert O; Utiswannakul A; Kositchaiwat U
    J Med Assoc Thai; 1990 Apr; 73(4):191-7. PubMed ID: 2394955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects.
    Flouvat B; Roux A; Leneveu A; Prinseau J; Alexandre JA
    Fundam Clin Pharmacol; 1991; 5(8):741-52. PubMed ID: 1783363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of seven furosemide tablets in man.
    Straughn AB; Wood GC; Raghow G; Meyer MC
    Biopharm Drug Dispos; 1986; 7(2):113-20. PubMed ID: 3708119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and pharmacokinetic study of a slow-release formulation of furosemide in man.
    Ebihara A; Tawara K; Oka T
    Arzneimittelforschung; 1983; 33(1):163-6. PubMed ID: 6681970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furosemide kinetics and dynamics in patients with cirrhosis.
    Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bio-availability of four formulations of furosemide.
    Meyer BH; Müller FO; Swart KJ; Luus HG; Werkman IM
    S Afr Med J; 1985 Oct; 68(9):645-7. PubMed ID: 3904040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.
    McNamara PJ; Foster TS; Digenis GA; Patel RB; Craig WA; Welling PG; Rapaka RS; Prasad VK; Shah VP
    Pharm Res; 1987 Apr; 4(2):150-3. PubMed ID: 3509139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men.
    Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT
    Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
    Kakuda TN; Leopold L; Timmers M; Van De Casteele T; Hillewaert V; Tomaka FL; Hoetelmans RM
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):805-16. PubMed ID: 25109510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of furosemide in patients with hepatic cirrhosis.
    González G; Arancibia A; Rivas MI; Caro P; Antezana C
    Eur J Clin Pharmacol; 1982; 22(4):315-20. PubMed ID: 7106167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.